Saving Lives Through Innovation

Genexine



Corporate Overview
Neil Warma, President and CEO

KBIC
July 12, 2022

Disclaimer

This Presentation has been prepared by Genexine Inc.for the purpose of setting out certain confidential information in respect of Genexine's business activities and strategy. References to this Presentation include any information which has been or may be supplied in writing or orally in connection with this Presentation or in connection with any further inquiries in respect of this Presentation. This Presentation is for the exclusive use of the recipients to whom it is addressed.

This Presentation and the information contained herein may be confidential. In addition to the terms of any confidentiality undertaking that a recipient may have entered into with Genexine, by its acceptance of this Presentation, each recipient agrees that it will not, and it will procure that each of its agents, representatives, advisors, directors or employees (collectively, "Representatives"), will not, and will not permit any third party to, copy, reproduce or distribute to others this Presentation, in whole or in part, at any time without the prior written consent of Genexine, and that it will keep confidential all information contained herein not already in the public domain and will use this Presentation for the sole purpose of setting out [familiarizing itself with] certain limited background information concerning Genexine and its business strategy and activities. This Presentation is not intended to serve as basis for any investment decision. If a recipient has signed a confidentiality undertaking with Genexine, this Presentation also constitutes Confidential Information for the purposes of such undertaking.

While the information contained in this Presentation is believed to be accurate, the Preparers have not conducted any investigation with respect to such information. The Preparers expressly disclaim any and all liability for representations or warranties, expressed or implied, contained in, or for omissions from, this Presentation or any other written or oral communication transmitted to any interested party in connection with this Presentation so far as is permitted by law. In particular, but without limitation, no representation or warranty is given as to the achievement or reasonableness of, and no reliance should be placed on, any projections, estimates, forecasts, analyses or forward looking statements contained in this Presentation which involve by their nature a number of risks, uncertainties or assumptions that could cause actual results or events to differ materially from those expressed or implied in this Presentation. Only those particular representations and warranties which may be made in a definitive written agreement, when and if one is executed, and subject to such limitations and restrictions as may be specified in such agreement, shall have any legal effect. By its acceptance hereof, each recipient agrees that none of the Preparers nor any of their respective Representatives shall be liable for any direct, indirect or consequential loss or damages suffered by any person as a result of relying on any statement in or omission from this Presentation, along with other information furnished in connection therewith, and any such liability is expressly disclaimed.

Except to the extent otherwise indicated, this Presentation presents information as of the date hereof. The delivery of this Presentation shall not, under any circumstances, create any implication that there will be no change in the affairs of Genexine after the date hereof. In furnishing this Presentation, the Preparers reserve the right to amend or replace this Presentation at any time and undertake no obligation to update any of the information contained in this Presentation or to correct any inaccuracies that may become apparent.

This Presentation shall remain the property of Genexine. Genexine may, at any time, request any recipient, or its Representatives, shall promptly deliver to Genexine or, if directed in writing by Genexine, destroy all confidential information relating to this Presentation received in written, electronic or other tangible form whatsoever, including without limitation all copies, reproductions, computer storage devices or written materials which contain such confidential information. At such time, all other notes, analyses or compilations constituting or containing confidential information in the recipient's, or their Representatives', possession shall be destroyed. Such destruction shall be certified to Genexine by the recipient in writing.

Neither the dissemination of this Presentation nor any part of its contents is to be taken as any form of commitment on the part of the Preparers or any of their respective affiliates to enter any contract or otherwise create any legally binding obligation or commitment. The Preparers expressly reserve the right, in their absolute discretion, without prior notice and without any liability to any recipient to terminate discussions with any recipient or any other parties.

This Presentation does not constitute or form part of any offer or invitation to sell, or any solicitation of any offer to purchase any shares in Genexine, nor shall it or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any contract or commitment or investment decisions relating thereto, nor does it constitute a recommendation regarding the shares in Genexine.

No securities commission or regulatory authority in any country has in any way opined upon the accuracy or adequacy of this Presentation or the materials contained herein. This Presentation is not, and under no circumstances is to be construed as, a prospectus, a public offering or an offering memorandum as defined under applicable securities laws and shall not form the basis of any contract.

The distribution of this Presentation in certain jurisdictions may be restricted by law and, accordingly, recipients of this Presentation represent that they are able to receive this Presentation without contravention of any unfulfilled registration requirements or other legal restrictions in the jurisdiction in which they reside or conduct business.

Genexine: A New Era of Growth and Opportunity

"Focused on the Development of Innovative biologics and Saving the Lives of Patients."

Corporate Highlights

- **Genexine is embracing a positive change in direction, leadership and shareholder focus**
- **Targeting product commercialization and global growth**
- **The next 12-24 months should see Genexine launch its first commercial products and establish operations in the US**

Genexine's goal is to become the first global Korean biopharmaceutical company

Key Executive Members

Professional leadership from discovery through clinical development, CMC and commercialization

CEO
Neil K. Warma

US GM, I-Mab Biopharma
CEO, Opexa Therapeutics
CEO, Viron Therapeutics
Founder, President, MedExact
Global Mktg, Policy, Novartis Pharma,
Univ. of Toronto HBSc, neuroscience
York Univ. MBA

COO/CEO
Jungwon Woo

SNU MS Pharmacology
Cornell Univ. PhD. Microbiology
Harvard Medical School post doc
Research Professor, Seoul St. Mary's Hospital

CFO
Sung-June Hong

Yonsei Univ. MBA
Vanderbilt Law School LLM
Daewoo Motors, Philip Morris, Nike Korea, Handok CFO
President of Rokit Healthcare

CMO
Jong-Sub Park

Professor, MD
Catholic Univ. College of Medicine
Catholic University
Director of Gynecological Cancer Center
Johns Hopkins
Exchange Professor

VP, Corp Dev
Hyun-Jin Park

SKKU Pharmacy
Aalto Univ. MBA
GSK Korea sales/marketing
Daewoong Pharma
Executive director, Development division

VP, Clinical Dev
Min-Kyu Heo

Yonsei Univ. MMed
JW Creagen Clinical Team
JW Pharma Clinical Team

VP, CMC
Ki-Yong Kim

Yonsei University
Ph.D. Biochemistry
NIH Postdoctoral Fellow
Mokam Biotechnology Res. Center
Green Cross Res. Inst.

Neil Warma: New CEO - Industry Leader

Background and expertise

2019-2022: I-Mab: U.S. GM/CEO (public)
- Global Immuno oncology company
- Offices: Shanghai, Beijing, San Diego, Maryland, Hong Kong

2017-2019: CEO for 2 MD Anderson oncology spin-outs (private)
- Led two oncology start-ups from MD Anderson Cancer Center

2008-2016: CEO Opexa Therapeutics (public)
- Public Immunotherapy company

2004-2007: CEO Viron Therapeutics (private)
- Protein therapeutics company

2000-2003: Founder, President MedExact (private)
- Medical technology company

1992-2000: Executive at Novartis Pharmaceuticals (public)
- Global Marketing, Global leader Policy and International Affairs

Two Proprietary Platforms yield late-stage candidates

hyFc™ (Long-acting protein drugs)



Long-acting platform technology which can be applied to various APIs to maximize protein sustainability.

DNA vaccine (Cancer therapeutic/ Infectious disease)

Therapeutic + Preventive DNA vaccine platform with strong T cell immunity.

A **Clinical Stage** biotech company developing **First-in-Class & Best-in-Class** products derived from two **proprietary platforms**

Two on-going Phase 3 trials, targeting **multiple BLA submissions** in the next 2-4 years

Head office in **Seoul, Korea**, **expansion into U.S.** in next 12 months; ability to conduct **global drug development**

Access to multiple **novel drugs** and platforms through **extensive strategic partnerships**

Pipeline Overview: Multiple Clinical Assets, On-going Ph 3 trials

Pipeline	Indication	Clinical Stage			Developer	Collaborator
		Phase 1	Phase 2	Phase 3		
GX-E4	CKD-induced Anemia	Phase 2 in KR		Phase 3 in Asia	Genexine, KG Bio, CWB	KGbio, 凯茂生物 CHEMO WANBANG BIOPHARMA
GX-H9	Growth Hormone Deficiency (PGHD)	Phase 2 in KR/EU		Phase 3 in CN	Genexine/Handok I-MAB	HANDOK, I-MAB BIOPHARMA
	Growth Hormone Deficiency (AGHD)	Phase 2 in KR/EU			Genexine/Handok	HANDOK
GX-I7	mTNBC, GBM, Skin cancer etc.	Phase 1~2 in KR/US/CN			Genexine, I-MAB NeoImmuneTech	MERCK, Roche, I-MAB BIOPHARMA, NEOIMMUNETECH
GX-P1	Autoimmune disease Organ transplantation	Phase 1 in KR			Genexine, GenNBio	GenNBio (주)제넨바이오, TURRET CAPITAL
GX-188E	Cervical cancer	Phase 2 in KR			Genexine	MERCK*
GX-G3	Neutropenia	Phase 2 in EU			ILKOGEN, I-MAB	ILKOGEN, I-MAB BIOPHARMA

Completed | Ongoing

Growth Strategy:

Genexine the 1st global Bio Venture company from Korea

Commercialization Strategy

Near Term Growth will come from executing clinical milestones

Globalization Strategy



Mid-term Growth will come through access to novel assets, people and markets

We have demonstrated our research strength …Shareholders awaiting execution & transition to a global development company

Executing the 2-stage strategy will drive tremendous value

3-5 Year plan

We need to be laser focused on key milestones

Inflection points will drive valuation and stock movement



Stage 1: Commercialization Strategy

Near-term growth … shifting into high gear



We must achieve these targets: Significant opportunity to add tremendous value in next 6-12 months

Genexine's Commercialization Plan

Multiple BLA submissions over next 5 years (based on current status)

2023	2024-2025			2025-
GX-188E +Keytruda® (conditional approval)	**GX-I7** (NT-I7) +Keytruda® (conditional approval)	**GX-E4**	**GX-H9**	**GX-I7** +Temozolomide
				
Cervical cancer	CRC/PaC/ TNBC/GBM	CKD-induced Anemia	Growth Hormone Deficiency	GBM
Phase 2 (Korea)	Phase 2 (Korea/US)	Phase 3 (Asia)	Phase 3 (China)	Phase 2 (China)

Our world in the next 3-5 years

Global Footprint
Multiple locations focused on global drug development
Listed on two stock exchanges

Financial Strength
Revenue Generating
Strong Cash Balance
Tremendous increase in Valuation
$3-5 Bn



Product Excellence
3-4 Products commercialized
Next generation of first-in-class assets in clinical dev.
Global partnering deals (LO and LI)

World Class Talent
Building a culture of growth & development
Where employees thrive and belong
Building internal talent pipeline

Key Product Overviews

1) GX-I7 (long acting interleukin-7)
2) GX-188 (DNA vaccine)
3) GX-H9 (long acting human growth hormone)
4) Gx-E4 (long acting EPO)



GX-I7 Long-acting Interleukin 7
(efineptakin alfa)

First-in-Class T-cell amplifier

GX-I7: The Only Solution for Lymphopenia

- Only clinical-stage long-acting human IL-7 drug candidate
- No lymphopenia correction drugs have been approved, to date
- IL-7 fundamental cytokine for naïve and memory T-cell development and sustaining immune response
- Favorable PK/PD and safety profile, for combination with Checkpoint Inhibitors or CAR-T therapies.
- Multiple ongoing trials in solid tumors, and in planning for hematologic malignancies

Erythrocyte	Platelet	Neutrophil	Lymphocyte
EPO (Erythropoietin) Anemia	**TPO (Thrombopoietin) Thrombocytopenia**	**G-CSFs Neutropenia**	**GX-I7 (Efineptakin alfa) Lymphopenia**
Epogen: Amgen Mircera: Roche	Nplate: Amgen Promacta: Novartis	Neupogen: Amgen Neulasta: Amgen	GX-I7 (NT-I7 / TJ-107)
Global Market **$ 10.7bn** in 2025 from $ 7.3bn in 2018	**Global Market** **$3.3bn** in 2025 from $ 3.0bn in 2018	**Global Market** **$15.4bn** in 2025 from $ 11.3bn in 2018	

GX-I7: The First Long-acting Lymphopenia Correction Drug Candidate

Hybrid Fc-fused long-acting recombinant human IL-7 which plays an essential role in the development and homeostasis of T-cells



N-terminal engineering

hyFc®

: Fc fusion of IgD + IgG4

No cytotoxicity on target cells
(No ADCC of IgD & No CDC of IgG4)

- **Higher protein stability**
- **Higher productivity**
- **Longer *in vivo* half-life**

T cell Amplifier

Long-acting Interleukin-7



T cell Activator

- Cancer vaccine
- IL-2, IL-15, IFN-alpha
- CD137 L, OX40 L, ICOSL
- TLR agonists, etc

T cell Suppressor blockade

- anti-PD-1, anti-PD-L1
- anti-CTLA4
- anti-TIM-3, anti-TIGIT
- anti-TGF-beta

GX-I7(NT-I7/TJ-107): Clinical Development

GX IMAB NIT

Field	Type	Treatment	Indication	Preclinical	Phase 1	Phase 2	Phase 3	Partner
Oncology	COM	KEYTRUDA®	TNBC	Phase 1b/2, KEYNOTE-899				MERCK, NeoImmuneTech
	COM	Avastin	Recurrent GBM	Phase 2				Roche
	COM	GX-188E/Opdivo	Recurrent HNSCC (HPV16)	Phase 2a				
	Mono	-	Solid Tumor	Phase 1/2a (STM101)				Genexine, NeoImmuneTech
	COM	Temozolomide	GBM	Phase 2 (GBM201)				
	COM	Pembrolizumab	TNBC, HNSCC	Phase 2 (STM202)				
	Mono	-	GBM (n=75)	Phase 1 (NIT-104, Single dose)				Johns Hopkins University
	COM	Temozolomide	GBM (n=46)	Phase 1/2 (NIT-107)				Washington University in St. Louis School of Medicine
	COM	Tecentriq®	High risk skin cancer	Phase 1b/2a (NIT-106)				Roche, cancer immunotherapy trials network
	COM	KEYTRUDA®	TNBC, Lung, Pancreatic, Colorectal cancer	Phase 1b/2a (NIT-110), KEYNOTE-A60				MERCK
	COM	Opdivo®	Gastric, GEJ, and Esophageal Adenocarcinomas	Phase 2 (NIT-109)				Bristol Myers Squibb
	COM	Tecentriq®	NSCLC, Non-Small Cell Lung Cancer	Phase 2 (NIT-119)				Roche
	Mono	-	Recurrent GBM	Phase 1 (NIT-115)				UCSF
	Mono	-	Kaposi's sarcoma	Phase 1 (NIT-108)				Fred Hutch Cures Start Here
	COM	Kymriah®	Diffuse large B-cell lymphoma	Phase 1b (NIT-112)				
Infectious Disease	Mono	-	Idiopathic $CD4^+$ T Lymphopenia	Under IND submission (NIT-114)				NIH National Institute of Allergy and Infectious Diseases
	COM	Vaccine	Preventative vaccine (Elderly cancer survivors)	Phase 1a/1b (NIT-105)				NIH National Cancer Institute
	Mono	standard	Covid19 treatment	Phase 1b				
	Mono	standard	Covid19 treatment	Phase 2				KGbio
	Mono	standard	Covid19 treatment	Phase 1 (NIT-116)				NIH National Institute of Allergy and Infectious Diseases
	Mono	-	Progressive polysomal leukoencephalitis	Phase 1 (NIT-113)				NIH National Institute of Allergy and Infectious Diseases

GX-I7 (NT-I7) : Promising Efficacy and Safety in mTNBC

- **ASCO June 2022:** phase 1b/2 study of GX-I7 plus pembrolizumab in patients with R/R mTNBC
- **ORRs in patients with CPS≥10 were 60% (6/10) vs 0% (0/15) with CPS<10.**

Ph1b/2 Interim Result in mTNBC

Response (RECIST v1.1) N (%)	GX-I7/Pembrolizumab Simultaneous Treatment (N=84)			
	Ph1b/2 (N=84) Total	**Ph2 (N=33)** PR2D 1,200μg/kg		
ORR	15 (17.9)	7 (21.2)	**CPS≥10 N=10**	**6(60)**
			CPS<10 N=15	**0(0)**
DCR	28 (33.3)	10 (30.3)		
CR	-	-		
PR	15 (17.9)	7 (21.2)		
SD	13 (15.5)	3 (9.1)		
PD	54 (64.3)	21 (63.6)		

Source: ASCO 2022 Poster Presentation



GX-188E DNA Vaccine for Cervical Cancer and SCCHN

First-in-Class Drug Candidate

GX-188E: Therapeutic DNA Vaccine against HPV-based diseases

- Therapeutic DNA Vaccine for HPV genotypes 16 & 18 (responsible for 70% of cervical cancer)
- Rationally designed DNA vaccine to enhance HPV 16/18, E6- and E7-specific CD8 + T cell responses
- Electroporation improves delivery and uptake
- Dramatic increase in efficacy as combination therapy with Check Point Inhibitors (CPI)





Source; TJ Kim et al, Nat Commun.; YJ Choi et al, Clin Cancer Res., 2020; JW Youn et. al, Lancet Oncol, 2020

GX-188E + Keytruda: Overall Timeline & Current Status (Cervical Cancer)

Phase 2 clinical timeline

Product/Indication		1	2	3	4	5	6	7	8	9	10	11	12
GX-188E + KEYTRUDA® Cervical Cancer, >2L (n=60)				▲ ORR at W14	▲ ORR_W24 by Investigator			▲ ORR_W24 by BICR	Top line results ▲ DB lock	▲ ESMO 2022	▲ TLF		▲ CSR ▲ CA Sub.

Interim analysis

- (n=48/60 total) reported at ASCO 2021, results from ph2 for combination with Keytruda (KEYNOTE-567)
- **33 % ORR (16/48) with 6 CR and 10 PR.**
- 48.0% (12/25) ORR under condition of PD-L1 + patients, HPV 16 and SCC (squamous cell carcinoma).
- High safety and tolerability: similar AE level compared to Keytruda mono.

Expected Milestones

- Presentation of **top-line results** in 2H ’22 (possibly ESMO)
- Submission of conditional approval in Korea, early ’23
- Commercial plans:
  - On-going discussions with potential partners for Phase 3 and commercial
  - Evaluating commercial launch in Korean market by Genexine

GX-188E + CPI + GX-I7: Overall Timeline & Current Status (Head & Neck Cancer)

Product/Indication	Objectives	1	2	3	4	5	6	7	8	9	10	11	12
GX-188E+ GX-I7 + OPDIVO® r/m HNSCC, ≥2L (n=21)	▪ Anti-tumor PoC and safety of triple combo in HPV+ r/m HNSCC	IND App./Contract		IND Approval	Opdivo Register in site	Enroll & Tx.		FPI	Lead-in safety (n=3)		ORR at W9 (n=6)	LPI	
GX-188E+GX-I7 + KEYTRUDA® LA HNSCC (n=11)	▪ Safety of triple combo in LA HNSCC as neoadjuvant therapy ▪ Histological PoC of triple combo in tumor microenvironment	IND App./Contract			IND Approval	FPI	Enroll & Tx.			LPI			MPR data

Expected 2022 Milestones

- IND submissions Q1/2 ’22
- Last patient dosed Q4 ’22 for both studies

GX-H9 Long-acting Growth Hormone for Pediatric and Adult GHD

Best-in-Class Drug Candidate with dosing advantage and growth data



Phase 3 : GX-H9 (Long-Acting Growth Hormone Deficiency Treatment)

AGHD and PGHD

Growth Hormone Deficiency Treatment

Daily Injection	Weekly/Bi-weekly injection
312 ~ 365 shots/year	Weekly : 52 shots/year Bi-weekly : 26 shots/year

Clinical Unmet Needs
Long-Acting & Convenience

Clinical Trials

- **Ph3 Trial in China by I-Mab**
  - Ph3 approval: 2020 Oct.
  - FPI: 2021 Feb.
  - BLA: 2024 first half
  - Patients: n=165 (expected completion of recruitment 2H 2022)

Growth data comparison, 1st yr vs 2nd average growth

- **Weekly or bi-weekly based injection** clinical data for 5 to 12 yrs-old growth hormone deficiency patients.
- Growth rate continued in 2nd yr compared to 1st yr. (both weekly and bi-weekly)
- Growth rate continued even after switching to H9 2nd yr after injection of other growth hormone product during 1st yr. (both weekly and bi-weekly)
- Developing pen type injector for better convenience.

aHV at 1st and 2nd year by doses



Switching to GX-H9 at 1 year



* EOW : Every Other Week

GX-H9 Global Development Status

Early stage development	Global development	Global market

Genexine

HANDOK

GX-H9

Growth hormone deficiency-Pediatric
Ph1 in EU, Ph2 multi-national trial completed

Growth hormone deficiency-adult
Ph1 in EU, Ph2 multi-national trial completed

Co-developing with Handok
CMC improvement completed
- Purity
- Getting ready for mass-production end of 2021

L/O
(Oct. '13)

I-MAB BIOPHARMA

Ph3 in China (on going)

- Total deal $ 100mn (GX-H9, G6, G3 combined)
- **Sales milestone**
- **BLA submission expected 2024**
- **Expected Launch 2025**

- **China** (excl. HK, Macau, Taiwan)
- **Strategic alliance with Jumpcan Pharmaceutical for fast commercialization in China** (Nov. '21)

Genexine

- **Evaluating ROW Ph3 Pediatric Growth hormone deficiency**

L/O

America, EU, Korea, Japan ASEAN, MENA, Oceania.

GX-H9 Market & Competitive Landscape

- Pediatric growth hormone deficiency treatment, global market expected $6.0 B (CAGR6.4%) in 2030.
- Chinese pediatric growth hormone deficiency treatment market expected $3.2B (CAGR 15.7%) in 2030, 60% share of global market

Reference : F&S, CMBIS

Company	Genexine HANDOK	ascendis pharma	OPKO Pfizer	novo nordisk	GenSci 金赛药业	特宝生物 AMOYTOP BIOTECH
Product	GX-H9	TransCon hGH	somatrogon	somapacitan	Jintrolong®	Xiamen Amoytop Biotech
Frequency	**Weekly**	Weekly	Weekly	Weekly	Weekly	Weekly
Stage	I-MAB BIOPHARMA CN, Phase 3	US, Marketed (‘21.8) CN, Phase 3	US, BLA submission	US, Phase 3	CN, Marketed	CN, Phase 2/3
Orphan Drug Designation	FDA: Nov. 2016 EMA: July 2021	FDA: Apr. 2020 EMA: Oct. 2019	FDA: Sep. 2010 EMA: Jan.2013	EMA: Aug. 2018	-	-
# of Patients	n=165	n=150	n=224	n=200	n=1500	n=400
Height Velocity	**11.76cm/yr** (1.2mg/kg)	11.2cm/yr (0.24mg/kg)	10.12cm/yr (0.66mg/kg)	11.5cm/yr (0.16mg/kg)	2.26±0.87cm ~ 13.41±3.72cm/yr (0.2mg/kg)	-

GX-E4 Long-acting erythropoietin

Long-acting EPO with superior sustainability, efficacy, safety and price competitiveness



Phase 3 : GX-E4 (Long-acting EPO)

EPO(Erythropoietin)
Anemia treatment

1st Gen	2nd Gen	3rd Gen
3 shots/wk	1 shot/wk	Bi-weekly/monthly
Epogen (Amgen)	Aranesp (Amgen)	Mircera (Roche)
		Unmet needs Sustainability & safety

Clinical Trials

- **Phase 3 trial in multi-nations (2020 March~)**
  - CKD-induced Anemia (non-dialysis)
  - 7 countries: Korea, Australia, Taiwan, Indonesia, Malaysia, Philippines, Thailand.
  - Recruited 327 / 386(Dec. '21)
  - Non-inferiority study against Mircera

Competitiveness

Long-acting EPO drug with superior sustainability, efficacy, safety and **price competitiveness**



No mutation

Outstanding efficacy and safety

- High activity and efficacy
- Safely treat patients without hypersensitive immune reaction nor adverse events.

Price competitiveness

- Simplified production process
- Price competitive due to low mfg. cost

Superior sustainability

- Bi-weekly or monthly dose

Business Focus and Upcoming Milestones

Genexine leverages global development via strategic partnersh

Contract Date	Partner Company	Product	Territory
2014.07	BSK	GX-188E	China
2015.06	NeoImmuneTech	GX-I7	Europe/USA
2015.10	I-Mab	GX-H9, GX-G6, GX-G3 etc.	China
2016.02	CWB	GX-E4	China
2016.03	KG BIO	GX-E4	ASEAN
2017.12	I-Mab	GX-I7	China
2020.01	GENBIO	GX-P1, GX-P10	Worldwide
2020.12	Turret Capital	GX-P1	Worldwide
2021.02	KG BIO	GX-I7	ASEAN, MENA, Oceania, etc.

Genexine Investment Thesis

Poised for global expansion and value generation

- Genexine pursuing a global path to drug development that will enable it to leverage global markets, technology and capital
- With solid platform technologies and multiple first-in-class products, Genexine now in position to commercialize its first products over the next 2-3 years.
- Uniquely positioned to access novel technology in South Korea, Asia and the U.S. provides competitive advantage
- Globally networked and experienced leadership team for efficient execution of global development plan
- Key near-term clinical data readouts & inflection points will drive shareholder value

THANK YOU

For further information, please contact:
Genexine, Inc.
Investor Relations
Jongsoo.lee@genexine.com